Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma.
Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma.
复制标题
DOI：
10.1038/sj.bjc.6605411
复制
发表时间：
2009-12-15
影响因子：
8.8
通讯作者：
中科院分区：
文献类型：
--
作者：
We evaluated the efficacy of imatinib mesylate in addition to hydroxyurea in patients with recurrent glioblastoma (GBM) who were either on or not on enzyme-inducing anti-epileptic drugs (EIAEDs). A total of 231 patients with GBM at first recurrence from 21 institutions in 10 countries were enrolled. All patients received 500 mg of hydroxyurea twice a day. Imatinib was administered at 600 mg per day for patients not on EIAEDs and at 500 mg twice a day if on EIAEDs. The primary end point was radiographic response rate and secondary end points were safety, progression-free survival at 6 months (PFS-6), and overall survival (OS). The radiographic response rate after centralised review was 3.4%. Progression-free survival at 6 months and median OS were 10.6% and 26.0 weeks, respectively. Outcome did not appear to differ based on EIAED status. The most common grade 3 or greater adverse events were fatigue (7%), neutropaenia (7%), and thrombocytopaenia (7%). Imatinib in addition to hydroxyurea was well tolerated among patients with recurrent GBM but did not show clinically meaningful anti-tumour activity.
登录
查看更多内容
影响因子：
45.3
作者：
Dodd, Lori E.;Korn, Edward L.;Mooney, Margaret M.
通讯作者：
Mooney, Margaret M.
影响因子：
50.5
作者：
Dresemann, G
通讯作者：
Dresemann, G
影响因子：
3.9
作者：
Desjardins, Annick;Quinn, Jennifer A.;Reardon, David A.
通讯作者：
Reardon, David A.
影响因子：
11.4
作者：
Aloyz, R;Grzywacz, K;Panasci, L
通讯作者：
Panasci, L
影响因子：
45.3
作者：
Kaba, SE;Kyritsis, AP;Levin, VA
通讯作者：
Levin, VA